| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802671101011 | 267110101 | APIDRA INJ.SOL 100 U/ML 1 VIAL x 10 ML (ΦΙΑΛΙΔΙΟ ΓΥΑΛΙΝΟ) (ΦΙΑΛΙΔΙΟ ΓΥΑΛΙΝΟ) | 14.43 | 15.14 | 20.86 |
| 05/2018 | 2802671102049 | 267110204 | APIDRA INJ.SOL 100 U/ML 5 CARTRIDGESx 3 ML (ΦΥΣΙΓΓΙΑ ΓΥΑΛΙΝΑ) (ΦΥΣΙΓΓΙΑ ΓΥΑΛΙΝΑ) | 21.61 | 22.67 | 31.24 |
| 05/2018 | 2802671105026 | 267110502 | APIDRA INJ.SOL 100 IU/ML BT x 3 PF PEN (SOLO STAR) x 3 ML (SOLO STAR) x 3 ML | 13.08 | 13.72 | 18.91 |
For the treatment of Type 1 and 2 diabetes mellitus. Should be used in regimens including a long-acting or basal insulin analogue unless it is used in a continuous infusion pump. May be used with oral antidiabetic agents.
Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.
Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia.
Absolute bioavailability following subcutaneous administration is approximately 70%. Time to maximum plasma concentration is approximately 60 minutes.
42 minutes